Company intelligence / Profile preview

Ambria

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Positive Phase 2 results reported for ninerafaxstat in non-obstructive hypertrophic cardiomyopathy (IMPROVE-HCM trial); Phase 2b FORTITUDE-HCM trial initiated in 2025 with first patient randomized; positive clinical data from Phase 2 IMPROVE-DiCE trial in cardiometabolic HFpEF presented at ACC.25[5]

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Cytokinetics Inc. (investor and strategic partner)Hypertrophic Cardiomyopathy Association (clinical trial support)

Beyond the preview

Go deeper on Ambria.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambria.

Explore the full profile